Our Products
VPI-Benztropine
VPI-Benztropine is a synthetic compound resulting from the combination of the active portions of atropine and diphenhydramine. Benztropine possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism. Benztropine antagonizes the effect of acetylcholine. This decreases the imbalance between the neurotransmitters acetylcholine and dopamine, which may improve the symptoms of early Parkinson's disease.
VPI-Benztropine is recommended for all etiologic groups of parkinsonism - arteriosclerotic, postencephalitic, idiopathic and drug-induced. It can be effective at any stage of the disease, even when a patient has become bedridden. Often it is helpful in patients who have become unresponsive to other agents.
VPI-Ethacrynate Sodium
VPI-Ethacrynate Sodium injection belongs to a group of medicines called loop diuretics. Ethacrynate Sodium is administered to treat fluid retention (edema) and swelling that is caused by congestive heart failure, acute pulmonary oedema, renal oedema, hepatic cirrhosis with ascites or other medical conditions.
VPI-Ondansetron ODT
Ondansetron is a selective antagonist of the serotonin receptor subtype, 5-HT3. Its precise mode of action in the control of chemotherapy induced nausea and vomiting is not known. VPI-Ondansetron ODT (ondansetron) is indicated for:
- the prevention of nausea and vomiting associated with emetogenic chemotherapy, including high dose cisplatin, and radiotherapy.
- the prevention and treatment of post-operative nausea and vomiting. VPI-Ondansetron is available in 4mg and 8mg oral dissolve tablets (ODT)

Provincial Formulary Coverage
ListedInterchangeableNo Coverage
Product Name | BC | AB | SK | MB | ON | QC | NB | PE | NS | NL |
VPI-Benztropine DIN 02486822 | ||||||||||
VPI-Ethacrynate Sodium DIN 02462362 | ||||||||||
VPI-Ondansetron ODT 4 mg DIN 02444674 | ||||||||||
VPI-Ondansetron ODT 8 mg DIN 02444682 |